RU96119781A - APPLICATION OF 2-Phenyl-3-aroylbenzothiophenes to reduce the level of cholesterol in the serum, pharmaceutical composition - Google Patents

APPLICATION OF 2-Phenyl-3-aroylbenzothiophenes to reduce the level of cholesterol in the serum, pharmaceutical composition

Info

Publication number
RU96119781A
RU96119781A RU96119781/04A RU96119781A RU96119781A RU 96119781 A RU96119781 A RU 96119781A RU 96119781/04 A RU96119781/04 A RU 96119781/04A RU 96119781 A RU96119781 A RU 96119781A RU 96119781 A RU96119781 A RU 96119781A
Authority
RU
Russia
Prior art keywords
pharmaceutical composition
cholesterol
day
reduce
aroylbenzothiophenes
Prior art date
Application number
RU96119781/04A
Other languages
Russian (ru)
Other versions
RU2150275C1 (en
Inventor
Уильям Дрейпер Майкл
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/205,012 external-priority patent/US5478847A/en
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of RU96119781A publication Critical patent/RU96119781A/en
Application granted granted Critical
Publication of RU2150275C1 publication Critical patent/RU2150275C1/en

Links

Claims (7)

1. Применение соединения формулы 1
Figure 00000001

или его фармацевтически приемлемой соли, или сольвата в количестве 55 - 150 мг/день для снижения уровня сывороточного холестерина.1. The use of the compounds of formula 1
Figure 00000001

or a pharmaceutically acceptable salt or solvate thereof in an amount of 55 to 150 mg / day to lower serum cholesterol. 2. Применение по п. 1, отличающееся тем, что соединение представляет гидрохлоридную соль. 2. The use according to claim 1, characterized in that the compound is a hydrochloride salt. 3. Применение по п.1, отличающееся тем, что количество соединения 60 - 100 мг/день. 3. The use according to claim 1, characterized in that the amount of compound 60 is 100 mg / day. 4. Применение по п. 1, отличающееся тем, что количество соединения 60 мг/день. 4. The use according to claim 1, characterized in that the amount of the compound is 60 mg / day. 5. Фармацевтическая композиция в виде стандартной лекарственной формы, пригодной для введения для снижения холестерина в сыворотке, содержащая в стандартной дозе 55 - 150 мг соединения формулы 1
Figure 00000002

или его фармацевтически приемлемой соли, или сольвата.5. The pharmaceutical composition in the form of a standard dosage form suitable for administration to reduce serum cholesterol, containing in a standard dose of 55 to 150 mg of the compounds of formula 1
Figure 00000002

or a pharmaceutically acceptable salt or solvate thereof. 6. Фармацевтическая композиция по п.5, отличающаяся тем, что содержит указанное соединение в количестве 60 - 100 мг/день. 6. The pharmaceutical composition according to claim 5, characterized in that it contains the specified compound in an amount of 60 to 100 mg / day. 7. Фармацевтическая композиция по п.5, отличающаяся тем, что содержит указанное соединение в количестве 60 мг/день. 7. The pharmaceutical composition according to claim 5, characterized in that it contains the specified compound in an amount of 60 mg / day.
RU96119781/14A 1994-03-02 1995-02-28 Use of 2-phenyl-3-aroylbenzothiophenes for serum blood cholesterol decrease, pharmaceutical composition RU2150275C1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/205,012 US5478847A (en) 1994-03-02 1994-03-02 Methods of use for inhibiting bone loss and lowering serum cholesterol
US08/205,012 1994-03-02

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU95102778/14A Division RU2100024C1 (en) 1994-03-02 1995-02-28 Use of 2-phenyl-3-aroylbenzothiephenes, their salts or solvates for inhibition of osseous tissue loss, pharmaceutical composition containing 2-phenyl-3-aroylbenzothiephenes and their salts or solvates

Publications (2)

Publication Number Publication Date
RU96119781A true RU96119781A (en) 1998-12-27
RU2150275C1 RU2150275C1 (en) 2000-06-10

Family

ID=22760425

Family Applications (2)

Application Number Title Priority Date Filing Date
RU95102778/14A RU2100024C1 (en) 1994-03-02 1995-02-28 Use of 2-phenyl-3-aroylbenzothiephenes, their salts or solvates for inhibition of osseous tissue loss, pharmaceutical composition containing 2-phenyl-3-aroylbenzothiephenes and their salts or solvates
RU96119781/14A RU2150275C1 (en) 1994-03-02 1995-02-28 Use of 2-phenyl-3-aroylbenzothiophenes for serum blood cholesterol decrease, pharmaceutical composition

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RU95102778/14A RU2100024C1 (en) 1994-03-02 1995-02-28 Use of 2-phenyl-3-aroylbenzothiephenes, their salts or solvates for inhibition of osseous tissue loss, pharmaceutical composition containing 2-phenyl-3-aroylbenzothiephenes and their salts or solvates

Country Status (23)

Country Link
US (5) US5478847A (en)
EP (1) EP0674903A1 (en)
JP (3) JP2818384B2 (en)
KR (1) KR950031069A (en)
CN (1) CN1119530A (en)
AU (1) AU702575B2 (en)
BR (1) BR9500784A (en)
CA (1) CA2141999A1 (en)
CO (1) CO4340681A1 (en)
CZ (1) CZ31395A3 (en)
HU (1) HUT72638A (en)
IL (1) IL112593A0 (en)
MY (1) MY130157A (en)
NO (1) NO950774L (en)
NZ (2) NZ270460A (en)
PE (1) PE44895A1 (en)
PH (1) PH31420A (en)
PL (1) PL307463A1 (en)
RU (2) RU2100024C1 (en)
SG (1) SG46354A1 (en)
UA (1) UA32636C2 (en)
YU (1) YU13695A (en)
ZA (1) ZA95976B (en)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
USRE38968E1 (en) * 1992-07-28 2006-02-07 Eli Lilly And Company Methods for inhibiting bone loss using 6-hydroxy-2-(4-hydroxyphenyl)-benzo[b]thien-3-yl-4-[2-(piperidin-1-yl) ethoxyphenylimethanone hydrochloride
USRE39049E1 (en) 1992-07-28 2006-03-28 Eli Lilly And Company Methods for inhibiting bone loss
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
US5770609A (en) 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
JPH08510451A (en) 1993-05-13 1996-11-05 ネオルックス コーポレイション Prevention and treatment of pathogenesis associated with hyperproliferative smooth muscle cells
WO1996040098A2 (en) 1995-06-07 1996-12-19 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
US5554601A (en) * 1993-11-05 1996-09-10 University Of Florida Methods for neuroprotection
US6319914B1 (en) 1993-11-05 2001-11-20 Apollo Biopharmaceuticals, Inc. Cytoprotective effect of polycyclic phenolic compounds
US5478847A (en) 1994-03-02 1995-12-26 Eli Lilly And Company Methods of use for inhibiting bone loss and lowering serum cholesterol
US5512583A (en) * 1995-01-30 1996-04-30 Eli Lilly And Company Methods of decreasing serum calcium levels
US5856340A (en) 1995-02-28 1999-01-05 Eli Lilly And Company Method of treating estrogen dependent cancers
US5726168A (en) * 1995-10-12 1998-03-10 Eli Lilly And Company Lipophilic benzothiophenes
US6458811B1 (en) 1996-03-26 2002-10-01 Eli Lilly And Company Benzothiophenes formulations containing same and methods
DK0910369T3 (en) 1996-03-26 2010-07-26 Lilly Co Eli Benzothiophenes, formulations containing the same and methods
US6440421B1 (en) * 1996-04-18 2002-08-27 Auchkland Uniservices Limited Treatment of bone disorders with adrenomedullin or adrenomedullin agonists
US5888963A (en) * 1996-04-18 1999-03-30 Auckland Uniservices Limited Treatment of bone disorders with adrenomedullin
US5747509A (en) * 1996-06-03 1998-05-05 Schering Aktiengesellschaft Method for lowering plasma levels of lipoprotein(a)
AU727708B2 (en) * 1996-06-20 2000-12-21 Board Of Regents, The University Of Texas System Compounds and methods for providing pharmacologically active preparations and uses thereof
CZ300261B6 (en) * 1996-10-30 2009-04-01 Eli Lilly And Company Use of raloxifene hydrochloride salt for preparing a medicament preventing breast cancer in a human
KR100522646B1 (en) * 1996-10-30 2005-12-21 일라이 릴리 앤드 캄파니 Methods of Preventing Breast Cancer
KR19980033284A (en) * 1996-10-30 1998-07-25 피터지.스트링거 Improved Breast Cancer Prevention
GB9624800D0 (en) * 1996-11-29 1997-01-15 Lilly Co Eli Methods of preventing breast cancer
US6069175A (en) * 1996-11-15 2000-05-30 Pfizer Inc. Estrogen agonist/antagonists treatment of atherosclerosis
WO1999016406A2 (en) 1997-09-26 1999-04-08 Auckland Uniservices Limited Therapeutic method
US6096781A (en) 1997-11-14 2000-08-01 Eli Lilly And Company 2-arylbenzo[B]thiophenes useful for the treatment of estrogen deprivation syndrome
US6054446A (en) 1997-12-24 2000-04-25 Sri International Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use
EP1067839A1 (en) * 1998-04-08 2001-01-17 Eli Lilly And Company Pulmonary and nasal delivery of raloxifene
US20040176470A1 (en) * 1998-05-07 2004-09-09 Steiner Mitchell S. Method for treatment and chemoprevention of prostate cancer
US7005428B1 (en) 1998-06-11 2006-02-28 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US6465445B1 (en) 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US6258826B1 (en) 1998-10-13 2001-07-10 Eli Lilly And Company Pharmaceutical formulations and applications thereof for the treatment of estrogen deprivation syndrome
WO2000066612A1 (en) 1999-05-04 2000-11-09 Strakan Limited Androgen glycosides and androgenic activity thereof
US6339078B1 (en) 1999-07-20 2002-01-15 University Of Florida Research Foundation, Inc. Methods of prevention and treatment of ischemic damage
US6326365B1 (en) 1999-07-20 2001-12-04 Apollo Biopharmaceutics, Inc. Methods of prevention and treatment of ischemic damage
US20020013327A1 (en) * 2000-04-18 2002-01-31 Lee Andrew G. Compositions and methods for treating female sexual dysfunction
AR029538A1 (en) * 2000-07-06 2003-07-02 Wyeth Corp PHARMACEUTICAL COMPOSITIONS OF ESTROGEN AGENTS
WO2002034266A1 (en) * 2000-10-25 2002-05-02 Eli Lilly And Company Method for inhibiting cataracts
US6599921B2 (en) 2001-02-22 2003-07-29 Nanodesign, Inc. Non-steroidal estrogen receptor ligands
EP1312363A1 (en) * 2001-09-28 2003-05-21 Pfizer Products Inc. Methods of treatment and kits comprising a growth hormone secretagogue
IL163666A0 (en) 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
US7342884B2 (en) * 2002-03-13 2008-03-11 Harmonic, Inc. Method and apparatus for one directional communications in bidirectional communications channel
JP3887588B2 (en) * 2002-08-30 2007-02-28 株式会社リガク Stress measurement method by X-ray diffraction
CA2499819A1 (en) 2002-09-30 2004-04-08 A/S Gea Farmaceutisk Fabrik Novel raloxifene acid addition salts and/or solvates thereof, improved method for purification of said raloxifene acid addition salts and/or solvates thereof and pharmaceutical compositions comprising these
US20060106010A1 (en) * 2003-05-27 2006-05-18 Black Larry J Methods for inhibiting bone loss
MXPA06003122A (en) * 2003-09-19 2006-05-31 Pfizer Prod Inc Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an estrogen agonist/antagonist.
CA2549935A1 (en) * 2003-12-17 2005-07-07 Pfizer Products Inc. Treatment of conditions that present with low bone mass by continuous combination therapy with selective prostaglandin ep4 receptor agonists and an estrogen
US20050137264A1 (en) * 2003-12-22 2005-06-23 Patel Ashish A. Modafinil compositions
US20050203086A1 (en) * 2004-03-04 2005-09-15 Pfizer Inc. Methods of treatment using an EP2 selective receptor agonist
US20050227966A1 (en) * 2004-04-08 2005-10-13 Wyeth Bazedoxifene acetate formulations
US7504394B2 (en) * 2004-04-08 2009-03-17 Wyeth Bazedoxifene ascorbate
US20060068010A1 (en) * 2004-09-30 2006-03-30 Stephen Turner Method for improving the bioavailability of orally delivered therapeutics
US8367105B2 (en) * 2004-11-10 2013-02-05 Teva Pharmaceutical Industries, Ltd. Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby
CA2587295A1 (en) * 2004-11-10 2006-05-18 Teva Pharmaceutical Industries Ltd. Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby
UA89513C2 (en) * 2004-12-03 2010-02-10 Элан Фарма Интернешнл Лтд. Nanoparticulate raloxifene hydrochloride composition
US20060270641A1 (en) * 2005-05-31 2006-11-30 Steiner Mitchell S Method for chemoprevention of prostate cancer
AU2009251563A1 (en) * 2008-04-02 2009-12-03 Dr. Reddy's Laboratories Ltd. Raloxifene pharmaceutical formulations
ES2437916T3 (en) 2009-07-02 2014-01-15 Synthon B.V. Raloxifene composition
US8501690B2 (en) 2010-04-30 2013-08-06 John G. Stark Use of selective estrogen receptor modulator for joint fusion and other repair or healing of connective tissue
JP5508311B2 (en) * 2011-02-28 2014-05-28 テバ ファーマシューティカル インダストリーズ リミティド Method for producing a compressed solid dosage form well suited for use with low water-soluble drugs and compressed solid dosage form produced thereby
AU2012353660A1 (en) 2011-12-16 2014-06-12 Olema Pharmaceuticals, Inc. Novel benzopyran compounds, compositions and uses thereof
WO2014203129A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Combinations of benzopyran compounds, compositions and uses thereof
WO2014203132A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Substituted benzopyran compounds, compositions and uses thereof
BR112018006121B1 (en) 2015-10-01 2024-01-23 Olema Pharmaceuticals, Inc TETRAHYDRO-1H-PYRIDO[3,4-b]INDOL COMPOUNDS, COMPOSITIONS COMPRISING SAID COMPOUNDS AND USES THEREOF
WO2017100715A1 (en) 2015-12-09 2017-06-15 The Board Of Trustees Of The University Of Illinois Benzothiophene-based selective estrogen receptor downregulator compounds
CN109641874A (en) 2016-05-10 2019-04-16 C4医药公司 C for target protein degradation3The glutarimide degron body of carbon connection
WO2017197036A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
CN109562107A (en) 2016-05-10 2019-04-02 C4医药公司 Heterocycle degron body for target protein degradation
EP3478294A4 (en) 2016-07-01 2020-06-10 G1 Therapeutics, Inc. Pyrimidine-based antiproliferative agents
WO2018081168A2 (en) 2016-10-24 2018-05-03 The Board Of Trustees Of The University Of Illinois Benzothiophene-based selective mixed estrogen receptor downregulators
EA201991622A1 (en) 2017-01-06 2020-01-23 Г1 Терапьютикс, Инк. COMPLEX THERAPY FOR TREATMENT OF CANCER
JP2020507566A (en) 2017-02-10 2020-03-12 ジー１ セラピューティクス， インコーポレイテッド Benzothiophene estrogen receptor modulator
EA201992768A1 (en) 2017-06-29 2020-05-19 Г1 Терапьютикс, Инк. MORPHOLOGICAL FORMS G1T38 AND METHODS FOR PRODUCING THEM
CN113453679A (en) 2018-12-20 2021-09-28 C4医药公司 Targeted protein degradation
WO2024030968A1 (en) 2022-08-03 2024-02-08 Brystol-Myers Squibb Company Compounds for modulating ret protein

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4185108A (en) 1977-05-10 1980-01-22 Westwood Pharmaceuticals Inc. Antiosteoporotic agents
IL65379A0 (en) 1981-04-03 1982-05-31 Lilly Co Eli Process for preparing acylated benzothiophenes
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
IL65404A0 (en) 1981-04-03 1982-07-30 Lilly Co Eli Benzothiophene compounds and process for preparing them
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
EP0068563A3 (en) 1981-06-23 1983-06-15 THE PROCTER & GAMBLE COMPANY Heterocyclic acetic acid compounds and compositions for treating bone diseases
US4729999A (en) 1984-10-12 1988-03-08 Bcm Technologies Antiestrogen therapy for symptoms of estrogen deficiency
US4970237A (en) 1987-03-20 1990-11-13 Yale University Use of clomiphene to increase bone mass in premenopausal women
US5075321A (en) * 1987-03-24 1991-12-24 University Of Pennsylvania Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
US5395842A (en) 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
US5208031A (en) 1989-06-06 1993-05-04 Kelly Patrick D Sexual lubricants containing zinc as an anti-viral agent
US5011853A (en) 1989-08-25 1991-04-30 Washington University Compounds for treatment of cholinergic neurotoxins
US5118667A (en) 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
DE4122484A1 (en) * 1991-07-06 1993-01-07 Teves Gmbh Alfred CIRCUIT FOR DETECTING WHEEL SENSOR DEFECTS
DE4123368C1 (en) 1991-07-15 1992-11-05 Bergwerksverband Gmbh, 4300 Essen, De
JP3157882B2 (en) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 New benzothiophene derivatives
AU3126593A (en) * 1991-11-25 1993-06-28 Healthguard, Incorporated Multistage coaxial encapsulated filter assembly
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
TW383306B (en) * 1992-12-22 2000-03-01 Lilly Co Eli New use of 2-phenyl-3-aroylbenzothiophenes in lowering serum cholesterol
US5482949A (en) 1993-03-19 1996-01-09 Eli Lilly And Company Sulfonate derivatives of 3-aroylbenzo[b]thiophenes
US5445941A (en) 1993-06-21 1995-08-29 Eli Lilly And Company Method for screening anti-osteoporosis agents
DE69405491T2 (en) 1993-06-24 1998-02-19 Lilly Co Eli Anti-estrogens 2-phenyl-3-aroylbenzothiophenes as hypoglycemic agents
TW303299B (en) 1993-07-22 1997-04-21 Lilly Co Eli
US5441947A (en) 1993-08-25 1995-08-15 Eli Lilly And Company Methods of inhibiting vascular restenosis
US5468773A (en) 1993-08-25 1995-11-21 Eli Lilly And Company Methods for inhibiting bone loss and cartilage degradation using wortmannin and its analogs
US5461065A (en) 1993-10-15 1995-10-24 Eli Lilly And Company Methods for inhibiting endometriosis
US5457116A (en) 1993-10-15 1995-10-10 Eli Lilly And Company Methods of inhibiting uterine fibrosis
RU2135176C1 (en) 1993-12-14 1999-08-27 Эли Лилли Энд Компани Water-dissolved inclusion complex of benzothiophene compounds with water-soluble cyclodextrin, method of synthesis and pharmaceutical composition
US5462949A (en) 1993-12-21 1995-10-31 Eli Lilly And Company Methods of inhibiting fertility in women
US5591753A (en) 1994-01-28 1997-01-07 Eli Lilly And Company Combination treatment for osteoporosis
US5972383A (en) 1994-03-02 1999-10-26 Eli Lilly And Company Solid orally administerable raloxifene hydrochloride pharmaceutical formulation
US5811120A (en) 1994-03-02 1998-09-22 Eli Lilly And Company Solid orally administerable raloxifene hydrochloride pharmaceutical formulation
US5478847A (en) * 1994-03-02 1995-12-26 Eli Lilly And Company Methods of use for inhibiting bone loss and lowering serum cholesterol
CO4410191A1 (en) 1994-09-19 1997-01-09 Lilly Co Eli SYNTHESIS OF 3- [4- (2-AMINOETOXI) BENZOIL] -2-ARYL-6- HYDROXYBENZO [b] THIOPHENES
US5629425A (en) 1994-09-19 1997-05-13 Eli Lilly And Company Haloalkyl hemisolvates of 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-piperidinoethoxy)-benzoyl]benzo[b]thiophene
US6458811B1 (en) 1996-03-26 2002-10-01 Eli Lilly And Company Benzothiophenes formulations containing same and methods
US6713494B1 (en) 1996-08-28 2004-03-30 Eli Lilly And Company Amorphous benzothiophenes, methods of preparation and methods of use
ID24978A (en) 1997-11-14 2000-08-31 Lilly Co Eli 2-ARYL-3-AROYLBENZO (b) USE THIOPHENES FOR TREATMENT OF ESTROGEN DEPRIVATION SYNDROME
US6096781A (en) 1997-11-14 2000-08-01 Eli Lilly And Company 2-arylbenzo[B]thiophenes useful for the treatment of estrogen deprivation syndrome
US6258826B1 (en) 1998-10-13 2001-07-10 Eli Lilly And Company Pharmaceutical formulations and applications thereof for the treatment of estrogen deprivation syndrome

Similar Documents

Publication Publication Date Title
RU96119781A (en) APPLICATION OF 2-Phenyl-3-aroylbenzothiophenes to reduce the level of cholesterol in the serum, pharmaceutical composition
KR950031069A (en) How to suppress bone loss and lower serum cholesterol
RU2350327C2 (en) Compounds causing weight loss
RU93004970A (en) Derivatives of cycloalkyl-substituted glutaramide, their use, pharmaceutical composition
KR950016725A (en) How to suppress pulmonary hypertension diseases
MX9504034A (en) Medical administering forms containing tioctic acid, or tioctic acid solid salts having improved release and bioavailability.
KR950016732A (en) How to suppress skin and vaginal atrophy
KR950010892A (en) How to suppress uterine fibrosis
KR950016731A (en) How to suppress seborrhea and acne
KR950016726A (en) How to suppress dysfunctional uterine bleeding
KR950010889A (en) How to inhibit angiogenesis and angiogenic diseases
KR950016724A (en) How to increase libido in women after menopause
KR950016742A (en) How to Suppress CNS Disease in Postmenopausal Women
KR950016735A (en) How to suppress Turner syndrome
ZA922910B (en) Heterocylic pharmaceutical compounds preparation and use
IT9019112A1 (en) PHARMACEUTICAL COMPOSITIONS AND DOSAGE FORMS FOR THE ORAL ADMINISTRATION OF CALCITONIN
CA2250191A1 (en) Benzothiophenes, formulations containing same, and methods
EP0743065A3 (en) Vanadium compounds for inhibiting bone loss
RU92004583A (en) PHARMACEUTICAL COMPOSITION AND METHOD FOR ITS PREPARATION
KR970704432A (en) REMEDY FOR HYPERLIPIDEMIA
RU98101105A (en) NEW APPLICATION FOR MEDICAL PURPOSES
KR880004810A (en) Peptic Ulcer Treatment
KR970705387A (en) METHODS OF INHIBITING ENDOMETRIAL CANCER
KR970706819A (en) Inhibiting Conditions Related to Bradykinin (Methods of Inhibiting Conditions Associated with Bradykinin)
KR980002033A (en) Triazole derivatives or salts thereof